The portfolio Upsher-Smith acquires contains 19 solid-oral dosage products and one nasal product, all of which have been approved by the Food and Drug Administration but haven’t been marketed by Sandoz.
Forbes is reporting that that Lannett’s shares fell 12.9% on Monday following an announcement from the FDA that it would be withdrawing approval of Lannett’s Concerta generic. The drug treats attention deficit hyperactivity disorder, and the FDA said there might not be enough evidence that Lannett’s generic is bioequivalent to the reference product. (Forbes)
Drug overdoses have become the leading cause of accidental death in the United States, with 47,055 people dying in 2014 as a result of lethal drug overdoses — 18,893 of which were related to prescription pain relievers. One of the critical first lines of defense, the drug naloxone can reverse the effects of an overdose. But until recently it could only be accessed by prescription.